Alebund Pharmaceuticals (Jiangsu) Limited released an update on 26 June 2026 confirming the composition of its Board of Directors and the leadership of its four specialised committees.

The Board comprises eight members: • Executive Directors: Dr. Gavin Guoyao Xia (Chairman and Chief Executive Officer), Jin Tian (M.D.), Ms. Wang Yun and Dr. Zhang Huading • Non-executive Director: Dr. Lu An • Independent Non-executive Directors: Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai

Committee assignments are as follows: 1. Audit Committee – Chaired by Independent Non-executive Director Mr. Leung Chi Wai, with Dr. Xu Runhong and Dr. Zhui Chen as members. 2. Remuneration and Appraisal Committee – Chaired by Dr. Zhui Chen; members include Dr. Gavin Guoyao Xia and Dr. Xu Runhong. 3. Nomination Committee – Chaired by Dr. Xu Runhong, joined by Dr. Gavin Guoyao Xia and Dr. Zhui Chen. 4. Strategy Committee – Chaired by Dr. Zhang Huading, with Dr. Gavin Guoyao Xia and Dr. Zhui Chen serving as members.

The announcement formalises governance responsibilities across audit, remuneration, nomination and strategic oversight functions, underlining Alebund Pharma’s adherence to Hong Kong listing regulations and corporate governance best practices.